Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
AbbVie Inc. logo
ABBV
AbbVie Inc.
20:00:00
216.63 $
0.0000 (%0.00)
Previous Close: 221.23
Day Low₺215.37
Day High₺222.35
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

ABBV: AbbVie Inc. Financials

AbbVie Inc. Income Statement

Total revenue
Net income
Gross margin TTM
70.24%
Operating margin TTM
32.85%
Net profit margin TTM
6.91%
Return on investment TTM
-129.24%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue61,160,000,00056,334,000,00054,318,000,00058,054,000,000
Operating income20,091,000,0009,137,000,00012,757,000,00018,117,000,000
Net income4,226,000,0004,278,000,0004,863,000,00011,836,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue61,160,000,00056,334,000,00054,318,000,00058,054,000,000
Cost of revenue18,204,000,00016,904,000,00020,415,000,00017,414,000,000
Gross profit42,956,000,00039,430,000,00033,903,000,00040,640,000,000
Research and development expenses9,096,000,00012,791,000,0007,675,000,0006,510,000,000
General and administrative expenses0000
Selling and marketing expenses0000
Selling, general and administrative expenses14,010,000,00014,752,000,00012,872,000,00015,260,000,000
Other expenses-241,000,0002,750,000,000599,000,000753,000,000
Operating expenses22,865,000,00030,293,000,00021,146,000,00022,523,000,000
Cost and expenses41,069,000,00047,197,000,00041,561,000,00039,937,000,000
Net interest income-2,627,000,000-2,160,000,000-1,684,000,000-2,044,000,000
Interest income266,000,000648,000,000540,000,000186,000,000
Interest expense2,893,000,0002,808,000,0002,224,000,0002,230,000,000
Depreciation and amortization8,139,000,0008,386,000,0008,698,000,0008,467,000,000
EBITDA17,629,000,00014,910,000,00017,172,000,00024,174,000,000
EBIT9,490,000,0006,524,000,0008,474,000,00015,707,000,000
Non-operating income (excl. interest)10,601,000,0002,613,000,0004,283,000,0002,410,000,000
Operating income20,091,000,0009,137,000,00012,757,000,00018,117,000,000
Total other income/expenses (net)-13,494,000,000-5,421,000,000-6,507,000,000-4,640,000,000
Income before tax6,597,000,0003,716,000,0006,250,000,00013,477,000,000
Income tax expense2,364,000,000-570,000,0001,377,000,0001,632,000,000
Net income from continuing operations4,233,000,0004,286,000,0004,873,000,00011,845,000,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income4,226,000,0004,278,000,0004,863,000,00011,836,000,000
Net income deductions0000
Bottom line net income4,196,000,0004,238,000,0004,820,000,00011,782,000,000
EPS2237
Diluted EPS2237
Weighted average shares outstanding1,780,392,0001,769,000,0001,768,000,0001,771,000,000
Weighted average diluted shares outstanding1,774,000,0001,773,000,0001,773,000,0001,778,000,000

AbbVie Inc. Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
59,608,000,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets133,960,000,000135,161,000,000134,711,000,000138,805,000,000
Total liabilities137,188,000,000131,797,000,000124,314,000,000121,518,000,000
Total equity-3,270,000,0003,325,000,00010,360,000,00017,254,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents5,229,000,0005,524,000,00012,814,000,0009,201,000,000
Short-term investments28,000,00031,000,0002,000,00028,000,000
Cash and short-term investments5,257,000,0005,555,000,00012,816,000,0009,229,000,000
Net receivables12,589,000,00010,919,000,00011,155,000,00011,254,000,000
Accounts receivable12,589,000,00010,919,000,00011,155,000,00011,254,000,000
Other receivables0000
Inventory4,951,000,0004,181,000,0004,099,000,0003,579,000,000
Prepaid expenses0000
Other current assets6,265,000,0004,927,000,0004,932,000,0004,401,000,000
Total current assets29,062,000,00025,582,000,00033,002,000,00028,463,000,000
Property, plant and equipment (net)6,365,000,0005,134,000,0004,989,000,0004,935,000,000
Goodwill35,640,000,00034,956,000,00032,293,000,00032,156,000,000
Intangible assets52,641,000,00060,068,000,00055,610,000,00067,439,000,000
Goodwill and intangible assets88,281,000,00095,024,000,00087,903,000,00099,595,000,000
Long-term investments299,000,000279,000,000304,000,000241,000,000
Tax assets0000
Other non-current assets9,953,000,0009,142,000,0008,513,000,0005,571,000,000
Total non-current assets104,898,000,000109,579,000,000101,709,000,000110,342,000,000
Other assets0000
Total assets133,960,000,000135,161,000,000134,711,000,000138,805,000,000
Total payables6,691,000,0002,945,000,0003,688,000,0002,934,000,000
Accounts payable3,592,000,0002,945,000,0003,688,000,0002,934,000,000
Other payables3,099,000,000000
Accrued expenses2,219,000,0001,986,000,0001,802,000,0001,371,000,000
Short-term debt8,749,000,0006,804,000,0007,191,000,0004,302,000,000
Capital lease obligations (current)0000
Tax payables0000
Deferred revenue0000
Other current liabilities25,630,000,00027,014,000,00025,160,000,00020,931,000,000
Total current liabilities43,289,000,00038,749,000,00037,841,000,00029,538,000,000
Long-term debt59,608,000,00060,340,000,00052,167,000,00059,118,000,000
Capital lease obligations (non-current)711,000,000720,000,000762,000,000771,000,000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)7,962,000,0007,628,000,0008,633,000,0008,692,000,000
Other non-current liabilities25,618,000,00024,383,000,00024,911,000,00023,399,000,000
Total non-current liabilities93,899,000,00093,048,000,00086,473,000,00091,980,000,000
Other liabilities0000
Capital lease obligations711,000,000720,000,000762,000,000771,000,000
Total liabilities137,188,000,000131,797,000,000124,314,000,000121,518,000,000
Treasury stock-9,146,000,000-8,201,000,000-6,533,000,000-4,594,000,000
Preferred stock0000
Common stock18,000,00018,000,00018,000,00018,000,000
Retained earnings-15,493,000,000-7,900,000,000-1,000,000,0004,784,000,000
Additional paid-in capital22,495,000,00021,333,000,00020,180,000,00019,245,000,000
Accumulated other comprehensive income/loss-1,144,000,000-1,925,000,000-2,305,000,000-2,199,000,000
Other stockholders' equity0000
Total stockholders' equity-3,270,000,0003,325,000,00010,360,000,00017,254,000,000
Total equity-3,228,000,0003,364,000,00010,397,000,00017,287,000,000
Minority interest42,000,00039,000,00037,000,00033,000,000
Total liabilities and total equity133,960,000,000135,161,000,000134,711,000,000138,805,000,000
Total investments327,000,000310,000,000306,000,000269,000,000
Total debt69,068,000,00067,841,000,00060,120,000,00064,191,000,000
Net debt63,839,000,00062,317,000,00047,306,000,00054,990,000,000

AbbVie Inc. Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations19,030,000,00018,806,000,00022,839,000,00024,943,000,000
Cash from investing-6,643,000,000-20,820,000,000-2,009,000,000-623,000,000
Cash from financing-12,724,000,000-5,211,000,000-17,222,000,000-24,803,000,000
Net change in cash-295,000,000-7,290,000,0003,613,000,000-545,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income4,226,000,0004,286,000,0004,820,000,00011,845,000,000
Depreciation and amortization8,139,000,0008,386,000,0008,698,000,0008,467,000,000
Deferred income tax-492,000,000-1,449,000,000-2,889,000,000-1,931,000,000
Stock-based compensation955,000,000911,000,000747,000,000671,000,000
Change in working capital-2,362,000,000-2,782,000,0002,813,000,000-258,000,000
Accounts receivable-1,490,000,000207,000,00066,000,000-1,455,000,000
Inventory-234,000,000-319,000,000-417,000,000-686,000,000
Accounts payable951,000,000177,000,0003,840,000,0001,605,000,000
Other working capital-1,589,000,000-2,847,000,000-676,000,000278,000,000
Other non-cash items8,604,000,0009,454,000,0008,650,000,0006,149,000,000
Net cash from operating activities19,030,000,00018,806,000,00022,839,000,00024,943,000,000
Investments in property, plant and equipment-1,214,000,000-974,000,000-777,000,000-695,000,000
Acquisitions (net)-204,000,000-17,493,000,000-1,223,000,000-794,000,000
Purchases of investments-35,000,000-73,000,000-77,000,000-1,438,000,000
Sales/maturities of investments76,000,000555,000,00055,000,0001,530,000,000
Other investing activities-5,266,000,000-2,835,000,00013,000,000774,000,000
Net cash from investing activities-6,643,000,000-20,820,000,000-2,009,000,000-623,000,000
Net debt issuance-327,000,0007,350,000,000-4,149,000,000-12,433,000,000
Long-term net debt issuance-2,826,000,0007,350,000,000-4,149,000,000-12,433,000,000
Short-term net debt issuance2,499,000,000000
Net stock issuance-808,000,000-1,708,000,000-1,972,000,000-1,487,000,000
Net common stock issuance-808,000,000-1,708,000,000-1,972,000,000-1,487,000,000
Common stock issuance172,000,000000
Common stock repurchased-980,000,000-1,708,000,000-1,972,000,000-1,487,000,000
Net preferred stock issuance0000
Net dividends paid-11,657,000,000-11,025,000,000-10,539,000,000-10,043,000,000
Common dividends paid-11,657,000,000-11,025,000,000-10,539,000,000-10,043,000,000
Preferred dividends paid0000
Other financing activities68,000,000172,000,000-562,000,000-840,000,000
Net cash from financing activities-12,724,000,000-5,211,000,000-17,222,000,000-24,803,000,000
Effect of FX changes on cash42,000,000-65,000,0005,000,000-62,000,000
Net change in cash-295,000,000-7,290,000,0003,613,000,000-545,000,000
Cash at end of period5,229,000,0005,524,000,00012,814,000,0009,201,000,000
Cash at beginning of period5,524,000,00012,814,000,0009,201,000,0009,746,000,000
Operating cash flow19,030,000,00018,806,000,00022,839,000,00024,943,000,000
Capital expenditure-1,214,000,000-974,000,000-777,000,000-695,000,000
Free cash flow17,816,000,00017,832,000,00022,062,000,00024,248,000,000
Income taxes paid04,064,000,0004,702,000,0002,988,000,000
Interest paid02,811,000,0002,469,000,0002,546,000,000